vs
Side-by-side financial comparison of CEVA INC (CEVA) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
CEVA INC is the larger business by last-quarter revenue ($27.0M vs $18.6M, roughly 1.5× ENANTA PHARMACEUTICALS INC). On growth, CEVA INC posted the faster year-over-year revenue change (11.5% vs 9.8%). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -2.5%).
CEVA Logistics is a global logistics and supply chain company that operates both freight management and contract logistics. It was purchased by the CMA CGM group in 2019. Since this purchase, CMA CGM has acquired other logistics and transportation companies to merge with and develop CEVA Logistics, such as Ingram Micro Commerce & Lifecycle Services and GEFCO.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
CEVA vs ENTA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $27.0M | $18.6M |
| Net Profit | — | $-11.9M |
| Gross Margin | 86.2% | — |
| Operating Margin | -5.0% | -60.5% |
| Net Margin | — | -64.1% |
| Revenue YoY | 11.5% | 9.8% |
| Net Profit YoY | — | 46.4% |
| EPS (diluted) | — | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.0M | — | ||
| Q4 25 | $31.3M | $18.6M | ||
| Q3 25 | $28.4M | $15.1M | ||
| Q2 25 | $25.7M | $18.3M | ||
| Q1 25 | $24.2M | $14.9M | ||
| Q4 24 | $29.2M | $17.0M | ||
| Q3 24 | $27.2M | $14.6M | ||
| Q2 24 | $28.4M | $18.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.1M | $-11.9M | ||
| Q3 25 | $-2.5M | $-18.7M | ||
| Q2 25 | $-3.7M | $-18.3M | ||
| Q1 25 | $-3.3M | $-22.6M | ||
| Q4 24 | $-1.7M | $-22.3M | ||
| Q3 24 | $-1.3M | $-28.8M | ||
| Q2 24 | $-291.0K | $-22.7M |
| Q1 26 | 86.2% | — | ||
| Q4 25 | 88.1% | — | ||
| Q3 25 | 88.0% | — | ||
| Q2 25 | 86.2% | — | ||
| Q1 25 | 85.6% | — | ||
| Q4 24 | 88.5% | — | ||
| Q3 24 | 85.4% | — | ||
| Q2 24 | 89.7% | — |
| Q1 26 | -5.0% | — | ||
| Q4 25 | -1.3% | -60.5% | ||
| Q3 25 | -7.3% | -121.6% | ||
| Q2 25 | -17.5% | -103.2% | ||
| Q1 25 | -18.1% | -164.3% | ||
| Q4 24 | 0.3% | -138.8% | ||
| Q3 24 | -9.6% | -204.4% | ||
| Q2 24 | -0.1% | -134.6% |
| Q1 26 | — | — | ||
| Q4 25 | -3.5% | -64.1% | ||
| Q3 25 | -8.8% | -123.6% | ||
| Q2 25 | -14.4% | -99.7% | ||
| Q1 25 | -13.7% | -151.7% | ||
| Q4 24 | -5.9% | -131.4% | ||
| Q3 24 | -4.8% | -197.3% | ||
| Q2 24 | -1.0% | -126.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.42 | ||
| Q3 25 | — | $-0.88 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-1.06 | ||
| Q4 24 | — | $-1.05 | ||
| Q3 24 | — | $-1.36 | ||
| Q2 24 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.4M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.2M | $126.6M |
| Total Assets | $388.2M | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $21.4M | — | ||
| Q4 25 | $40.6M | $37.4M | ||
| Q3 25 | $17.3M | $32.3M | ||
| Q2 25 | $29.1M | $44.8M | ||
| Q1 25 | $18.8M | $60.2M | ||
| Q4 24 | $18.8M | $84.3M | ||
| Q3 24 | $13.2M | $37.2M | ||
| Q2 24 | $25.0M | $35.8M |
| Q1 26 | $338.2M | — | ||
| Q4 25 | $336.5M | $126.6M | ||
| Q3 25 | $268.7M | $64.7M | ||
| Q2 25 | $265.9M | $79.3M | ||
| Q1 25 | $269.1M | $93.5M | ||
| Q4 24 | $266.6M | $111.8M | ||
| Q3 24 | $265.8M | $128.8M | ||
| Q2 24 | $263.8M | $148.9M |
| Q1 26 | $388.2M | — | ||
| Q4 25 | $388.3M | $329.5M | ||
| Q3 25 | $306.0M | $280.7M | ||
| Q2 25 | $302.8M | $301.0M | ||
| Q1 25 | $310.0M | $323.0M | ||
| Q4 24 | $308.9M | $348.6M | ||
| Q3 24 | $304.9M | $376.7M | ||
| Q2 24 | $300.4M | $398.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.7M |
| Free Cash FlowOCF − Capex | — | $-11.8M |
| FCF MarginFCF / Revenue | — | -63.6% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.7M | $-11.7M | ||
| Q3 25 | $-5.9M | $-6.5M | ||
| Q2 25 | $1.2M | $17.5M | ||
| Q1 25 | $-7.4M | $-13.5M | ||
| Q4 24 | $8.0M | $-16.8M | ||
| Q3 24 | $399.0K | $-10.4M | ||
| Q2 24 | $2.4M | $-14.8M |
| Q1 26 | — | — | ||
| Q4 25 | $7.2M | $-11.8M | ||
| Q3 25 | $-6.3M | $-7.9M | ||
| Q2 25 | $492.0K | $17.4M | ||
| Q1 25 | $-7.7M | $-16.0M | ||
| Q4 24 | $7.0M | $-25.5M | ||
| Q3 24 | $-15.0K | $-19.4M | ||
| Q2 24 | $1.8M | $-21.3M |
| Q1 26 | — | — | ||
| Q4 25 | 23.1% | -63.6% | ||
| Q3 25 | -22.1% | -52.5% | ||
| Q2 25 | 1.9% | 94.7% | ||
| Q1 25 | -31.8% | -107.4% | ||
| Q4 24 | 24.0% | -150.6% | ||
| Q3 24 | -0.1% | -132.5% | ||
| Q2 24 | 6.2% | -118.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.8% | 0.8% | ||
| Q3 25 | 1.5% | 9.6% | ||
| Q2 25 | 2.7% | 0.8% | ||
| Q1 25 | 1.3% | 17.0% | ||
| Q4 24 | 3.5% | 51.6% | ||
| Q3 24 | 1.5% | 61.3% | ||
| Q2 24 | 2.1% | 36.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CEVA
| Licensing and related revenues | $17.8M | 66% |
| Royalties | $9.2M | 34% |
ENTA
Segment breakdown not available.
